Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease

DOI: 10.1093/hmg/ddw122
Human Molecular Genetics, 2016, 25, 2621-2632.

#	Paper	IF	Citations
52	Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. *Experimental Neurology*, **2016**, 283, 121-8	5.7	20
51	Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. *Scientific Reports*, **2016**, 6, 31652	4.9	43
50	Complex spatial and temporally defined myelin and axonal degeneration in Huntington disease. *NeuroImage: Clinical*, **2018**, 20, 236-242	5.3	23
49	Identification of distinct conformations associated with monomers and fibril assemblies of mutant huntingtin. *Human Molecular Genetics*, **2018**, 27, 2330-2343	5.6	12
48	A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes. *Human Molecular Genetics*, **2018**, 27, 2125-2137	5.6	12
47	Genetic Rodent Models of Huntington Disease. *Advances in Experimental Medicine and Biology*, **2018**, 1049, 29-57	3.6	13
46	Overview of Huntington's Disease Models: Neuropathological, Molecular, and Behavioral Differences. *Current Protocols in Neuroscience*, **2018**, 83, e47	2.7	10
45	A critical review of brain and cognitive reserve in Huntington's disease. *Neuroscience and Biobehavioral Reviews*, **2018**, 88, 155-169	9	21
44	Huntington's disease leads to decrease of GABA-A tonic subunits in the D2 neostriatal pathway and their relocalization into the synaptic cleft. *Neurobiology of Disease*, **2018**, 110, 142-153	7.5	11
43	Brain Regions Showing White Matter Loss in Huntington's Disease Are Enriched for Synaptic and Metabolic Genes. *Biological Psychiatry*, **2018**, 83, 456-465	7.9	54
42	Therapeutic approaches to Huntington disease: from the bench to the clinic. *Nature Reviews Drug Discovery*, **2018**, 17, 729-750	64.1	74
41	Gradual Phenotype Development in Huntington Disease Transgenic Minipig Model at 24 Months of Age. *Neurodegenerative Diseases*, **2018**, 18, 107-119	2.3	12
40	A role for autophagy in Huntington's disease. *Neurobiology of Disease*, **2019**, 122, 16-22	7.5	61
39	Transgenic minipig model of Huntington's disease exhibiting gradually progressing neurodegeneration. *DMM Disease Models and Mechanisms*, **2019**, 13,	4.1	7
38	Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models. *Neurotherapeutics*, **2019**, 16, 957-978	6.4	18
37	Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 9622-9627	11.5	26
36	Impaired Remyelination in a Mouse Model of Huntington Disease. *Molecular Neurobiology*, **2019**, 56, 6873-6882	6.2	8

35	Manipulation of microbiota reveals altered callosal myelination and white matter plasticity in a model of Huntington disease. *Neurobiology of Disease*, **2019**, 127, 65-75	7.5	24
34	Motivational Impairment is Accompanied by Corticoaccumbal Dysfunction in the BACHD-Tg5 Rat Model of Huntington's Disease. *Cerebral Cortex*, **2019**, 29, 4763-4774	5.1	1
33	Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease. *Molecular Neurobiology*, **2019**, 56, 4464-4478	6.2	19
32	Human ESC-Derived Chimeric Mouse Models of Huntington's Disease Reveal Cell-Intrinsic Defects in Glial Progenitor Cell Differentiation. *Cell Stem Cell*, **2019**, 24, 107-122.e7	18	33
31	Myelin Breakdown in Human Huntington's Disease: Multi-Modal Evidence from Diffusion MRI and Quantitative Magnetization Transfer. *Neuroscience*, **2019**, 403, 79-92	3.9	29
30	Potential Circadian Rhythms in Oligodendrocytes? Working Together Through Time. *Neurochemical Research*, **2020**, 45, 591-605	4.6	10
29	Lipid rafts and neurodegeneration: structural and functional roles in physiologic aging and neurodegenerative diseases. *Journal of Lipid Research*, **2020**, 61, 636-654	6.3	32
28	Drumming Motor Sequence Training Induces Apparent Myelin Remodelling in Huntington's Disease: A Longitudinal Diffusion MRI and Quantitative Magnetization Transfer Study. *Journal of Huntington's Disease*, **2020**, 9, 303-320	1.9	2
27	A Critical Review of White Matter Changes in Huntington's Disease. *Movement Disorders*, **2020**, 35, 1302-1311	7	16
26	Diffusion-weighted MRI in neurodegenerative and psychiatric animal models: Experimental strategies and main outcomes. *Journal of Neuroscience Methods*, **2020**, 343, 108814	3	0
25	The contribution of glial cells to Huntington's disease pathogenesis. *Neurobiology of Disease*, **2020**, 143, 104963	7.5	23
24	Reprint of: Manipulation of microbiota reveals altered callosal myelination and white matter plasticity in a model of Huntington disease. *Neurobiology of Disease*, **2020**, 135, 104744	7.5	3
23	Oligodendroglial Heterogeneity in Neuropsychiatric Disease. *Life*, **2021**, 11,	3	2
22	Multi-compartment analysis of the complex gradient-echo signal quantifies myelin breakdown in premanifest Huntington□ disease.		
21	Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75 Ligand LM11A-31. *Neurotherapeutics*, **2021**, 18, 1039-1063	6.4	4
20	Expression of Reprogramming Factor OCT4 Ameliorates Myelination Deficits and Induces Striatal Neuroprotection in Huntington's Disease. *Genes*, **2021**, 12,	4.2	1
19	Identification of the key role of white matter alteration in the pathogenesis of Huntington□ Disease.		0
18	Human iPSC-derived neural precursor cells differentiate into multiple cell types to delay disease progression following transplantation into YAC128 Huntington's disease mouse model. *Cell Proliferation*, **2021**, 54, e13082	7.9	5

17	Early white matter pathology in the fornix of the limbic system in Huntington disease. *Acta Neuropathologica*, **2021**, 142, 791-806	14.3	1
16	Manipulation of microbiota reveals altered myelination and white matter plasticity in a model of Huntington disease.		1
15	Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. *JCI Insight*, **2017**, 2,	9.9	30
14	Striatal infusion of cholesterol promotes dose-dependent behavioral benefits and exerts disease-modifying effects in Huntington's disease mice. *EMBO Molecular Medicine*, **2020**, 12, e12519	12	4
13	Diffusion Tensor Imaging in Preclinical and Human Studies of Huntington's Disease: What Have we Learned so Far?. *Current Medical Imaging*, **2019**, 15, 521-542	1.2	10
12	Drumming motor sequence training induces apparent myelin remodelling in Huntington disease: a longitudinal diffusion MRI and quantitative magnetization transfer study.		
11	Dose-dependent and disease-modifying effects of striatal infusion of cholesterol in Huntington disease.		
10	Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
9	Mutation-related apparent myelin, not axon density, drives white matter differences in premanifest Huntington disease: Evidence from in vivo ultra-strong gradient MRI.		
8	Oligodendrocytes and Myelin: Active players in Neurodegenerative brains?. *Developmental Neurobiology*, **2022**,	3.2	0
7	Huntington Disease Gene Expression Signatures in Blood Compared to Brain of YAC128 Mice as Candidates for Monitoring of Pathology.. *Molecular Neurobiology*, **2022**, 1	6.2	
6	Mutation-related magnetization-transfer, not axon density, drives white matter differences in premanifest Huntington disease: Evidence from in vivo ultra-strong gradient MRI.. *Human Brain Mapping*, **2022**,	5.9	1
5	Single nuclei RNAseq analysis of HD mouse models and human brain reveals impaired oligodendrocyte maturation and potential role for thiamine metabolism.		
4	Mapping the glial transcriptome in Huntington disease using snRNAseq: Selective disruption of glial signatures across brain regions.		0
3	Astrocytic engagement of the corticostriatal synaptic cleft is disrupted in a mouse model of Huntington disease.		1
2	Early whole-body mutant huntingtin lowering preserves proteins and lipids important for synapse function and white matter maintenance in the LacQ140 mouse model.		0
1	Progressive alterations in white matter microstructure across the timecourse of Huntington's disease. **2023**, 13,		0